In May 2004, Spectrum announced a marketing and supply agreement with Shantha Biotechnics, a leading Indian biopharmaceutical company engaged in the development, manufacture and commercialization of human healthcare products produced by recombinant technology for the detection and treatment of cancer and infectious diseases.
Shantha Biotechnics currently markets its products in India and several other countries in Asia and the Middle East. Currently marketed products include interferon alpha 2b, streptokinase, and a recombinant hepatitis-B vaccine, among others. Shantha's development-stage product portfolio includes biotechnology products such as erythropoetin, G-CSF, insulin and tPA, as well as monoclonal antibodies directed at various cancer types, vaccines and diagnostic kits.
Under the terms of the agreement, Spectrum will be responsible for all regulatory, marketing and distribution matters in the United States for certain products currently marketed by Shantha elsewhere in the world and certain other products under development by Shantha. The product candidates include certain oncology biologics, cancer diagnostics, as well as certain vaccines.
Spectrum believes this alliance has the potential to support, strengthen and expand both its oncology and generic strategies by providing access to additional growth drivers, including differentiated capabilities and approaches that could provide for high quality, low-cost production of both proprietary as well as generic biologics for the US market.
Shantha Biotechnics – Website
